News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Halts Study of Doribax Antibiotic on Higher Death Rate


1/5/2012 3:51:03 PM

Johnson & Johnson (JNJ) halted a clinical trial of its antibiotic Doribax after more pneumonia patients who took the product died and fewer were cured, regulators said.

Doribax, already approved for urinary and abdominal infections in the U.S., is still considered safe and effective for those uses, the Food and Drug Administration said today in a statement on its website. The trial tested the drug in pneumonia patients who were on ventilators, an indication for which it’s approved in Europe.

Read at Bloomberg
Read at Baltimore Sun

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES